NCT03493451 2024-10-26Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsBeiGenePhase 2 Completed77 enrolled 20 charts
NCT03947255 2023-10-13A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell LymphomaSeagen Inc.Phase 2 Terminated12 enrolled 17 charts
NCT02939014 2021-02-24Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)TakedaPhase 2 Completed39 enrolled 26 charts
NCT04306887 2020-03-13A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 Unknown30 enrolled
NCT02465528 2019-12-27Ceritinib Rare Indications Study in ALK+ TumorsNovartisPhase 2 Terminated22 enrolled 16 charts
NCT00866047 2017-03-22A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaSeagen Inc.Phase 2 Completed58 enrolled 19 charts
NCT00947856 2017-02-02A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin StudySeagen Inc.Phase 2 Completed110 enrolled 15 charts
NCT00079755 2014-12-18Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaSeagen Inc.Phase 2 Completed80 enrolled
NCT00298467 2010-04-26MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell LymphomaBristol-Myers SquibbPhase 2 Withdrawn45 enrolled